History and Activities

R.E.D. Laboratories was founded in 1998 to develop and commercialize the pioneering work of Dr. Robert Suhadolnik at Temple University who in 1995 discovered the presence of an abnormal protein in a subset of patients with Chronic Fatigue Syndrome (CFS). This protein is related to a normal enzyme, Ribonuclease L (RNase L), one of the interferon-inducible enzymes, which protects the body during a viral infection. An increased amount of this abnormal protein defines a clinical subset of CFS patients.

In June 1998, to secure the scientific foundation of R.E.D. Laboratories, the Company obtained an exclusive license from Temple University on this technology. Subsequently, the Company began to offer assaying patient specimens for the abnormal protein on a fee-for-service basis.

In 2000 the Company started its own research and development activities on chronic immune diseases. Clinical assay development and research programs at R.E.D. Laboratories now focus on inflammatory mechanisms, oxidative stress, intestinal dysfunctions and viral infections, all disorders that contribute to the onset and pathogenesis of diseases such as CFS, multiple sclerosis, or autoimmune diseases.

As a specialty clinical laboratory, R.E.D. Laboratories now offers up to 40 different diagnostic tests to customers all around the world.

R.E.D. Laboratories facility in Zellik, Belgium: